IntegraGen’s Core Strategy is to deliver a portfolio of high-value molecular diagnostic products and services that drive personalized healthcare solutions for complex diseases. Development and commercialization activities are currently focused on Autism, Diabetes, Obesity and Bi-Polar disorders.  In-licencing and out-licensing are key strategic levers.
IntegraGen's Enabling Strategy leverages internal competencies , provides a foundation for future offerings and generating an in-flow of cash. The Genetic Services Business provides Genotyping Services and BAC-Array Chips to the research community.  IntegraGen's Center of Excellence for Diabetes, based in Bonn Germany, is ISO accredited and provides four highly specialized molecular diagnostic tests to healthcare professionals.

Our Business Model uses partnering to fund IP growth

Competitive Advantage

Our Competitive Advantage derives from the alignment of the company's valuable resources: 

  • Our People are dedicated and world-class Scientists, Bio-Statisticians and Technicians.
  • Our Technology, GenomeHIP™, is breakthrough. It is fast, cost-effective, and highly accurate in identifying causal genes.
  • Our Partners provide complementary expertise and privileged access to unique patient collections. 

Seminar 2009

Dr Bernard Courtieu spoke at the 3rd Meeting of the Pharmaceutical Industry in Barcelona. Date : November 5th, 2009.

His presentation focused on new approaches and business models to innovation for biotech markets.

More information : IESE Barcelona

Latest News

7-10 September 2009 : Prof. Andreas Ziegler, University of Lübeck, made a presentation on methods for Evaluating clinical validity in single affected offspring trio families. at 54. Jahrestagung der Deutschen Gesellschaft für Medizinische Informatik, Biometrie und Epidemiologie e.V. (GMDS) conference in Essen (Germany)

>> link to abstract

>> link to GMDS conference

 

9 june 2009 : Bernard Courtieu, CEO of IntegraGen, attended the AMIPS* conference on "Drug development for personalised medicine". His presentation focused on biomarkers development for Neurology.

*AMIPS : Association des Médecins des Industries des Produits de Santé (French association of Medical doctors of health industry products)

link to AMIPS